Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016323 | 1.00 | CHRNA7 (1.00) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL1792876 | 0.91 | CHRNA7 (0.82) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL1792880 | 0.91 | CHRNA7 (0.82) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL930335 | 0.87 | CHRNA7 (0.78) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL930336 | 0.87 | CHRNA7 (0.78) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL930767 | 0.87 | CHRNA7 (0.77) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL927574 | 0.85 | CHRNA7 (0.74) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL927575 | 0.85 | CHRNA7 (0.74) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL927821 | 0.84 | CHRNA7 (0.72) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 | |
| SCHEMBL927820 | 0.84 | CHRNA7 (0.72) | CHRNA7KCNH2HTR3ACHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | claimed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | claimed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | claimed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| EP-2931315-B1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9828642-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-20170296682-A1 | DERIVATIVES OF DIBENZOTHIOPHENE IMAGING OF alpha-7 NICOTINIC ACETYLCHOLINE RECEPTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-20160235869-A1 | DERIVATIVES OF DIBENZOTHIOPHENE IMAGING OF alpha-7 NICOTINIC ACETYLCHOLINE RECEPTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-08-18 | — | — | US | disclosed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-2038278-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002956-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | CHRNA7 4801/4885KCNH2 3938/4885HTR3A 2251/4885 |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885KCNH2 2953/4885HTR3A 112/4885 |
| US-20170296682-A1 | DERIVATIVES OF DIBENZOTHIOPHENE IMAGING OF alpha-7 NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNB2, CHRNB3 | CHRNA7 1/4885KCNH2 928/4885HTR3A 120/4885 |
| US-20160235869-A1 | DERIVATIVES OF DIBENZOTHIOPHENE IMAGING OF alpha-7 NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNB2, CHRNB3 | CHRNA7 1/4885KCNH2 928/4885HTR3A 120/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | CHRNA7 1/4885KCNH2 340/4885HTR3A 114/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885KCNH2 978/4885HTR3A 151/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885KCNH2 2953/4885HTR3A 112/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CHRNA7 1/4885KCNH2 765/4885HTR3A 38/4885 |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | OXA1L, CYP3A7, ABAT | CHRNA7 1540/4885KCNH2 2197/4885HTR3A 897/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885KCNH2 978/4885HTR3A 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.